Eurofins Reinforces Its Environment Testing Footprint with the Acquisition of EAC Corp. in Japan
May 02 2016 - 3:00AM
Business Wire
Regulatory News:
Eurofins Scientific (EUFI.PA) (Paris:ERF), the world leader in
environment testing services, announces that it has signed an
agreement to acquire EAC Corporation Ltd. (“EAC”) from Asahi
Industries Co., Ltd. (“Asahi”) in Japan. As part of the
acquisition, Asahi and Eurofins will enter into an exclusive
supplier contract for a period of 3 years. The transaction is
expected to close by the end of May.
EAC provides environment testing services nationwide, with a
strong competence in water and dioxin testing, and is one of the
leading laboratories in the Northern Kanto region of Japan.
Established in 1972, EAC employs about 70 staff and generates
revenues of about EUR 5m.
The acquisition of EAC reinforces Eurofins’ local footprint, as
well as its platform to further deploy the Group’s analytical
expertise, especially in water and dioxin testing. With a leading
position in Radioactive Material Analysis (RMA) following the
acquisition of Nihon Kankyo (2012) and Nihon Soken (2015), the
acquisition of EAC should allow Eurofins to also strengthen its
service offering in water and dioxin testing. Furthermore, EAC’s
site location is a strong geographic fit with Eurofins’ existing
presence in the Southern Kanto region. Therefore the operational
and geographic fit of this acquisition should allow the Group to
become a reference laboratory for environment testing in Japan.
Comment from Dr. Gilles Martin, Eurofins CEO: “EAC is a
good strategic fit to the Group’s existing activities in Japan.
This acquisition reinforces the Group’s growing Asia Pacific
footprint, and is a further demonstration of our commitment in the
region. We look forward to giving EAC access to the full
capabilities of the Eurofins network.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysis
Eurofins Scientific believes it is the world leader in food,
environment and pharmaceutical products testing, as well as one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 validated
analytical methods for evaluating the safety, identity,
composition, authenticity, origin, traceability and purity of
biological substances and products, as well as for innovative
clinical diagnostic. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities and healthcare
practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:This press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160502005449/en/
Investor RelationsEurofins Scientific GroupPhone: +32 2 766
1620E-mail: ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024